LiangbiaoGeorge Hu
Research Subjects
Research Interests
LiangbiaoGeorge Hu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Jason D Blom
Pfizer Global Research & Development, St. Louis Laboratories, Pfizer Inc, St. Louis, MO, 63017, USA
1 shared publicationJon G Selbo
Pfizer Global Research & Development, St. Louis Laboratories, Pfizer Inc, St. Louis, MO, 63017, USA
1 shared publicationKimberly Shevlin
Pfizer Global Research & Development, St. Louis Laboratories, Pfizer Inc, St. Louis, MO, 63017, USA
1 shared publicationNa Li
Pfizer Global Research & Development, St. Louis Laboratories, Pfizer Inc, St. Louis, MO, 63017, USA
1 shared publication- Po-Chang Chiang
Department of Pharmaceutical Science, Pfizer Global Research and Development, St. Louis Laboratories, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, USA
1 shared publication Timothy G Brayman
Pfizer Global Research & Development, St. Louis Laboratories, Pfizer Inc, St. Louis, MO, 63017, USA
1 shared publication
Latest Publications
- Open Access
- 9 September 2008
- Published by Springer Nature in Discover Nano
- Vol. 3 (9) , 321-329
Comparison of In vitro Nanoparticles Uptake in Various Cell Lines and In vivo Pulmonary Cellular Transport in Intratracheally Dosed Rat Model
In present study, the potential drug delivery of nanoformulations was validated via the comparison of cellular uptake of nanoparticles in various cell lines and in vivo pulmonary cellular uptake in intratracheally (IT) dosed rat model. Nanoparticles were prepared by a bench scale wet milling device and incubated with a series of cell lines, including Caco-2, RAW, MDCK and MDCK transfected MDR1 cells. IT dosed rats were examined for the pulmonary cellular uptake of nanoparticles. The processes of nanoparticle preparation did not alter the crystalline state of the material. The uptake of nanoparticles was observed most extensively in RAW cells and the least in Caco-2 cells. Efflux transporter P-gp did not prevent cell from nanoparticles uptake. The cellular uptake of nanoparticles was also confirmed in bronchoalveolar lavage (BAL) fluid cells and in bronchiolar epithelial cells, type II alveolar epithelial cells in the intratracheally administrated rats. The nanoparticles uptake in MDCK, RAW cells and in vivo lung epithelial cells indicated the potential applications of nanoformulation for poorly soluble compounds. The observed limited direct uptake of nanoparticles in Caco-2 cells suggests that the improvement in oral bioavailability by particle size reduction is via increased dissolution rate rather than direct uptake.
- 9 September 2008
- Published by Springer Nature in Discover Nano
- Vol. 3 (9) , 321-329
Open AccessComparison of In vitro Nanoparticles Uptake in Various Cell Lines and In vivo Pulmonary Cellular Transport in Intratracheally Dosed Rat Model
In present study, the potential drug delivery of nanoformulations was validated via the comparison of cellular uptake of nanoparticles in various cell lines and in vivo pulmonary cellular uptake in intratracheally (IT) dosed rat model. Nanoparticles were prepared by a bench scale wet milling device and incubated with a series of cell lines, including Caco-2, RAW, MDCK and MDCK transfected MDR1 cells. IT dosed rats were examined for the pulmonary cellular uptake of nanoparticles. The processes of nanoparticle preparation did not alter the crystalline state of the material. The uptake of nanoparticles was observed most extensively in RAW cells and the least in Caco-2 cells. Efflux transporter P-gp did not prevent cell from nanoparticles uptake. The cellular uptake of nanoparticles was also confirmed in bronchoalveolar lavage (BAL) fluid cells and in bronchiolar epithelial cells, type II alveolar epithelial cells in the intratracheally administrated rats. The nanoparticles uptake in MDCK, RAW cells and in vivo lung epithelial cells indicated the potential applications of nanoformulation for poorly soluble compounds. The observed limited direct uptake of nanoparticles in Caco-2 cells suggests that the improvement in oral bioavailability by particle size reduction is via increased dissolution rate rather than direct uptake.